The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Honoraria - Foundation Medicine; Guardant Health
Consulting or Advisory Role - Exenex
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Eisai (Inst); GSB Pharma (Inst); Incyte (Inst); Johnson & Johnson (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Omid Hamid
Honoraria - Array BioPharma; Bristol-Myers Squibb; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; Array BioPharma; BeiGene; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Array BioPharma; Bristol-Myers Squibb; Novartis; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Nektar
 
David R Wise
Employment - Best Doctors, Inc
Honoraria - OncLive
Consulting or Advisory Role - Alphasights; Foundation Medicine; Gerson Lehrman Group; Guidepoint Global; Leap Therapeutics; Pfizer; Silverlight
Travel, Accommodations, Expenses - Pfizer
 
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; CytomX Therapeutics; Protean Biodiagnostics
Honoraria - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Nektar; Novartis; Oncorus; Protean Biodiagnostics; Roche; Sellas Life Sciences; Takeda Science Foundation; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Merck; Novartis; Roche; Takeda
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Saba Shafi
No Relationships to Disclose
 
David L. Rimm
Stock and Other Ownership Interests - Pixel Gear
Honoraria - Amgen; Bristol-Myers Squibb; Ventana Medical Systems
Consulting or Advisory Role - Agendia; AstraZeneca; Bristol-Myers Squibb; Cell Signaling Technology; Cepheid; Daiichi Sankyo; GlaxoSmithKline; Konica Minolta; Merck; NanoString Technologies; NextCure; PAIGE.AI; Perkin Elmer; Roche; Sanofi; Ultivue
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Cepheid (Inst); Konica Minolta (Inst); Lilly (Inst); NanoString Technologies (Inst); Navigate Biopharma (Inst); NextCure (Inst); Perkin Elmer (Inst); Ultivue (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
Travel, Accommodations, Expenses - Bristol-Myers Squibb; NextCure; Ventana Medical Systems
 
Anthony W. Tolcher
Employment - Next Oncology; START
Leadership - Symphogen
Consulting or Advisory Role - AbbVie (Inst); AbGenomics International (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Axiom Biotechnologies (Inst); Bayer (Inst); BioInvent (Inst); Boston Biomedical (Inst); Cello Health (Inst); EMD Serono (Inst); Forbius (Inst); Genentech/Roche (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); Immunome (Inst); Immunome (Inst); Immunome (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); OSI Pharmaceuticals (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Ridgeway Therapeutics (Inst); Scientex (Inst); Seagen (Inst); Sesen Bio (Inst); Seven and Eight Biopharmaceuticals (Inst); Symphogen (Inst); Syneos Health (Inst)
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Boehringer Ingelheim (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
 
Debashree Basudhar
Employment - NextCure
Stock and Other Ownership Interests - NextCure
Patents, Royalties, Other Intellectual Property - University of Arizona
Travel, Accommodations, Expenses - NextCure
 
Melanie Elizabeth Dujka
Employment - NextCure
Stock and Other Ownership Interests - NextCure
Travel, Accommodations, Expenses - NextCure
 
Kevin N. Heller
Employment - NextCure
Leadership - NextCure
Stock and Other Ownership Interests - NextCure
Travel, Accommodations, Expenses - NextCure